Orexo AB
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for New Pharmaceutical Composition for Drug Delivery (US 11,737,980) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Pharmaceutical Composition for Nasal Delivery (US 11,883,392) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Pharmaceutical formulations useful in the treatment of insomnia (US 9,265,720) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Pharmaceutical Composition Comprising Adrenaline (US 11,957,647) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,597,281 | Pharmaceutical formulations useful in the treatment of insomnia In force · From the USPTO record | In force | From the USPTO record | |
| US 9,265,720 | Pharmaceutical formulations useful in the treatment of insomnia In force · From the USPTO record | In force | From the USPTO record | |
| US 10,653,690 | Pharmaceutical Composition for Nasal Delivery In force · High confidence | In force | High confidence | |
| US 10,729,687 | Pharmaceutical Composition for Nasal Delivery In force · High confidence | In force | High confidence | |
| US 10,898,480 | Pharmaceutical composition for nasal delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 11,883,392 | Pharmaceutical Composition for Nasal Delivery In force · High confidence | In force | High confidence | |
| US 12,268,684 | Pharmaceutical Composition for Nasal Delivery In force · High confidence | In force | High confidence | |
| US 11,737,980 | New Pharmaceutical Composition for Drug Delivery In force · High confidence | In force | High confidence | |
| US 12,357,573 | New Pharmaceutical Composition for Drug Delivery In force · High confidence | In force | High confidence | |
| US 12,138,259 | Method of controlling depression in subjects treated for opioid dependence In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 15: 16 patents in force now held by others · 13 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 9 abandoned · 15 no status recorded